ECSP12011573A - Compuestos tetracíclicos - Google Patents

Compuestos tetracíclicos

Info

Publication number
ECSP12011573A
ECSP12011573A EC2012011573A ECSP12011573A ECSP12011573A EC SP12011573 A ECSP12011573 A EC SP12011573A EC 2012011573 A EC2012011573 A EC 2012011573A EC SP12011573 A ECSP12011573 A EC SP12011573A EC SP12011573 A ECSP12011573 A EC SP12011573A
Authority
EC
Ecuador
Prior art keywords
useful
tetracyclic compounds
cancer
alk
formula
Prior art date
Application number
EC2012011573A
Other languages
English (en)
Inventor
Noriyuki Furuichi
Hiroki Sakamoto
Kasutomo Kinoshita
Kohsuke Asoh
Toshiya Ito
Hatsuo Kawada
Nobuya Ishii
Woosang Hong
Minjeong Park
Yoshiyuki Ono
Kenji Morikami
Takashi Emura
Nobuhiro Oikawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP2009139691 priority Critical
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of ECSP12011573A publication Critical patent/ECSP12011573A/es
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43308919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011573(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76Dibenzothiophenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0834Compounds having one or more O-Si linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

Un compuesto representado por la siguiente fórmula general (I), o una sal o solvato del mismo, que es de utilidad como un inhibidor de ALK, y útil para la profilaxis o el tratamiento de una enfermedad acompañada de anomalías de ALK, por ejemplo, cáncer, metástasis de cáncer, depresión o un trastorno de la función cognitiva:(el significado de los símbolos incluidos en la fórmula se describe en la memoria descriptiva).
EC2012011573A 2009-06-10 2012-01-04 Compuestos tetracíclicos ECSP12011573A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009139691 2009-06-10

Publications (1)

Publication Number Publication Date
ECSP12011573A true ECSP12011573A (es) 2012-02-29

Family

ID=43308919

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011573A ECSP12011573A (es) 2009-06-10 2012-01-04 Compuestos tetracíclicos

Country Status (39)

Country Link
US (4) US9126931B2 (es)
EP (4) EP3613729A1 (es)
JP (2) JP4588121B1 (es)
KR (1) KR101351120B1 (es)
CN (1) CN102459172B (es)
AR (1) AR077025A1 (es)
AU (1) AU2010259588B2 (es)
BR (1) BRPI1011649A2 (es)
CA (1) CA2764653C (es)
CL (1) CL2011002433A1 (es)
CO (1) CO6430460A2 (es)
CR (1) CR20110492A (es)
CY (1) CY1117752T1 (es)
DK (3) DK2441753T3 (es)
EC (1) ECSP12011573A (es)
ES (3) ES2575084T3 (es)
HK (1) HK1165794A1 (es)
HR (3) HRP20160605T1 (es)
HU (4) HUE046402T2 (es)
IL (1) IL216817A (es)
LT (3) LT2975024T (es)
LU (1) LUC00022I2 (es)
MA (1) MA33418B1 (es)
MX (1) MX2011013306A (es)
MY (1) MY159850A (es)
NL (1) NL300876I2 (es)
NO (2) NO2975024T3 (es)
NZ (1) NZ597477A (es)
PE (1) PE20121065A1 (es)
PL (3) PL3345903T3 (es)
PT (3) PT3345903T (es)
RS (1) RS58855B1 (es)
RU (2) RU2725140C2 (es)
SG (1) SG175707A1 (es)
SI (3) SI2441753T1 (es)
TW (2) TWI531367B (es)
UA (1) UA107796C2 (es)
WO (1) WO2010143664A1 (es)
ZA (1) ZA201106938B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725140C2 (ru) * 2009-06-10 2020-06-30 Чугаи Сейяку Кабусики Кайся Тетрациклические соединения
CA2808210C (en) 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 4環性化合物を含む医薬
KR102110794B1 (ko) * 2011-10-31 2020-05-15 더 메서디스트 하스피틀 리서치 인스티튜트 인간의 신경교종을 치료하기 위한 모노아마이드 옥시다아제(Monoamide oxidase,MAO) 타겟팅/시커(seeker) 부분(moiety)을 포함하는 조성물
DK2822939T3 (en) 2012-03-06 2016-03-14 Cephalon Inc Condensed bicycleic 2,4-diaminopyrimidine derivatives as dual alk and fak inhibitors
WO2014050781A1 (ja) 2012-09-25 2014-04-03 中外製薬株式会社 Ret阻害剤
MX2015008187A (es) * 2012-12-20 2016-02-05 Concert Pharmaceuticals Inc DEUTERED ALK INHIBITORS.
CN104968667B (zh) * 2013-02-05 2017-06-20 山东轩竹医药科技有限公司 四并环激酶抑制剂
US8927563B2 (en) * 2013-04-02 2015-01-06 Respivert Limited Kinase inhibitor
CN104109168B (zh) * 2013-04-20 2017-02-15 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104130241A (zh) * 2013-05-05 2014-11-05 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104177332A (zh) * 2013-05-20 2014-12-03 中国科学院上海药物研究所 酰胺基取代的吲哚并萘酮衍生物及其医药用途
CN104177342B (zh) * 2013-05-21 2018-01-05 中国科学院上海药物研究所 杂环基取代的吲哚并萘酮衍生物及其医药用途
CN105579459B (zh) * 2013-06-01 2018-03-13 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
US20160129003A1 (en) 2013-06-18 2016-05-12 Novartis Ag Pharmaceutical Combinations
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
KR20160142383A (ko) 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
SG10202009484WA (en) 2014-04-25 2020-11-27 Chugai Pharmaceutical Co Ltd Preparation containing tetracyclic compound at high dose
KR20170020783A (ko) * 2014-06-18 2017-02-24 에프. 호프만-라 로슈 아게 비이온성 계면활성제를 포함하는 약학 조성물
TW202115047A (zh) * 2014-08-08 2021-04-16 日商中外製藥股份有限公司 4環性化合物的非晶質體
WO2016050171A1 (zh) 2014-09-29 2016-04-07 山东轩竹医药科技有限公司 多环类间变性淋巴瘤激酶抑制剂
CN105566307B (zh) * 2014-10-11 2019-04-23 中国科学院上海药物研究所 一类杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) * 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
EP3268346B1 (en) * 2015-03-11 2021-05-05 International Flavors & Fragrances Inc. Processes for the preparation of unsaturated malonates
EP3287463A4 (en) 2015-04-24 2018-07-11 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
EP3353150A4 (en) * 2015-09-23 2019-06-19 Dana Farber Cancer Institute, Inc. ALK AND SRPK INHIBITORS AND METHODS OF USE
CN105777710B (zh) * 2016-04-05 2018-09-04 湖南欧亚药业有限公司 一种艾乐替尼的合成方法
CN106946650B (zh) * 2017-03-01 2021-06-08 南京远淑医药科技有限公司 一种盐酸阿雷替尼中间体的合成方法
CN107033125B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928125A (zh) * 2017-04-21 2017-07-07 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼中间体的制备方法
CN106892860B (zh) * 2017-04-21 2019-08-02 湖南博奥德药业有限公司 一种艾乐替尼中间体的制备方法
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106995433A (zh) * 2017-04-21 2017-08-01 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
JP2020518607A (ja) 2017-05-04 2020-06-25 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 植物病原菌を駆除するための置換5−(ハロアルキル)−5−ヒドロキシ−イソオキサゾール
US20200140427A1 (en) 2017-07-05 2020-05-07 Fresenius Kabi Oncology Limited A process for preparing alectinib or a pharmaceutically acceptable salt thereof
CN108178743A (zh) * 2018-02-08 2018-06-19 安庆奇创药业有限公司 一种艾乐替尼关键中间体的制备方法
WO2019211868A1 (en) * 2018-04-30 2019-11-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile hydrochloride
WO2020004630A1 (ja) 2018-06-29 2020-01-02 中外製薬株式会社 難溶性の塩基性薬剤を含有する医薬組成物
TW202024050A (zh) 2018-09-04 2020-07-01 日商中外製藥股份有限公司 四環性化合物的製造方法
AU2019348006A1 (en) * 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
CN109438218B (zh) * 2018-10-23 2021-04-09 成都艾必克医药科技有限公司 一种盐酸艾乐替尼中间体2-(4-乙基-3-碘苯基)-2-甲基丙酸的合成方法
CN109384664B (zh) * 2018-11-20 2021-04-13 成都正善达生物医药科技有限公司 一种艾乐替尼中间体的制备方法
EP3556754A1 (en) 2018-12-07 2019-10-23 Fresenius Kabi iPSUM S.r.l. Process for the preparation of alectinib
WO2020130125A1 (ja) 2018-12-21 2020-06-25 第一三共株式会社 抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) * 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
JPH08291285A (ja) * 1995-04-21 1996-11-05 Fuji Photo Film Co Ltd 感光性組成物及びそれを用いた要素
US5936084A (en) 1996-05-01 1999-08-10 Eli Lilly And Company Halo-substituted bisindolemaleimide protein kinase C inhibitors
US6632822B1 (en) * 1999-05-14 2003-10-14 The Australian National University Compounds and therapeutic methods
KR20050118169A (ko) * 2003-02-28 2005-12-15 이노텍 파마슈티컬스 코포레이션 사환식 벤즈아미드 유도체 및 이것의 사용 방법
DK1454992T3 (da) * 2003-03-07 2006-10-02 Ist Naz Stud Cura Dei Tumori Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス, インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
CN100548986C (zh) 2003-12-12 2009-10-14 默克弗罗斯特加拿大有限公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
WO2005090304A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
RU2008122547A (ru) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CL2007003049A1 (es) * 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
SI2176231T1 (sl) 2007-07-20 2017-01-31 Nerviano Medical Sciences S.R.L. Substituirani indazolni derivati, aktivni kot kinazni inhibitorji
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ido阻害剤
CN102574830A (zh) 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
RU2725140C2 (ru) * 2009-06-10 2020-06-30 Чугаи Сейяку Кабусики Кайся Тетрациклические соединения
CA2808210C (en) * 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
WO2014050781A1 (ja) * 2012-09-25 2014-04-03 中外製薬株式会社 Ret阻害剤
SG10202009484WA (en) * 2014-04-25 2020-11-27 Chugai Pharmaceutical Co Ltd Preparation containing tetracyclic compound at high dose
KR20160142383A (ko) * 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
KR20170020783A (ko) * 2014-06-18 2017-02-24 에프. 호프만-라 로슈 아게 비이온성 계면활성제를 포함하는 약학 조성물
TW202115047A (zh) * 2014-08-08 2021-04-16 日商中外製藥股份有限公司 4環性化合物的非晶質體

Also Published As

Publication number Publication date
HK1165794A1 (en) 2012-10-12
JP5628603B2 (ja) 2014-11-19
PL2975024T3 (pl) 2018-09-28
SI2441753T1 (sl) 2016-07-29
CY1117752T1 (el) 2017-05-17
CA2764653A1 (en) 2010-12-16
NZ597477A (en) 2014-03-28
LUC00022I1 (es) 2017-06-15
CN102459172B (zh) 2015-06-24
RU2015156881A (ru) 2019-01-18
CA2764653C (en) 2018-01-02
HRP20180615T1 (hr) 2018-06-01
SG175707A1 (en) 2011-12-29
HUE046402T2 (hu) 2020-03-30
LT3345903T (lt) 2019-12-10
HRP20192022T1 (hr) 2020-02-07
IL216817A (en) 2016-05-31
US20160340308A1 (en) 2016-11-24
ES2759510T3 (es) 2020-05-11
CL2011002433A1 (es) 2012-02-17
WO2010143664A1 (ja) 2010-12-16
KR20120034677A (ko) 2012-04-12
JP2011016830A (ja) 2011-01-27
EP2441753A4 (en) 2014-08-27
MX2011013306A (es) 2012-01-12
PL3345903T3 (pl) 2020-02-28
CO6430460A2 (es) 2012-04-30
TW201613858A (en) 2016-04-16
TWI624457B (zh) 2018-05-21
HUS1700026I1 (hu) 2017-07-28
EP2975024A1 (en) 2016-01-20
EP2975024B1 (en) 2018-03-28
DK3345903T3 (da) 2019-11-11
NO2975024T3 (es) 2018-08-25
IL216817D0 (en) 2012-02-29
EP2441753B1 (en) 2016-03-30
JPWO2010143664A1 (ja) 2012-11-29
SI3345903T1 (sl) 2020-02-28
EP3345903B1 (en) 2019-10-09
EP2441753A1 (en) 2012-04-18
SI2975024T1 (en) 2018-05-31
RS58855B1 (sr) 2019-07-31
PE20121065A1 (es) 2012-08-28
AU2010259588B2 (en) 2015-05-28
KR101351120B1 (ko) 2014-01-15
US20200017442A1 (en) 2020-01-16
UA107796C2 (en) 2015-02-25
CN102459172A (zh) 2012-05-16
US20150150845A1 (en) 2015-06-04
DK2975024T3 (en) 2018-04-23
TWI531367B (zh) 2016-05-01
LUC00022I2 (es) 2017-09-08
US9440922B2 (en) 2016-09-13
NL300876I1 (nl) 2017-06-14
ES2575084T3 (es) 2016-06-24
DK2441753T3 (en) 2016-05-30
TW201103537A (en) 2011-02-01
RS20110548A1 (en) 2012-08-31
LTPA2017017I1 (lt) 2017-06-26
JP4588121B1 (ja) 2010-11-24
ZA201106938B (en) 2012-12-27
RU2725140C2 (ru) 2020-06-30
MY159850A (en) 2017-02-15
LTC2441753I2 (lt) 2019-02-25
PL2441753T3 (pl) 2016-09-30
BRPI1011649A2 (pt) 2021-04-20
MA33418B1 (fr) 2012-07-03
PT2975024T (pt) 2018-05-14
NO2017026I1 (no) 2017-06-12
HRP20160605T1 (hr) 2016-07-01
EP3345903A1 (en) 2018-07-11
US9126931B2 (en) 2015-09-08
PT3345903T (pt) 2019-12-09
NO2017026I2 (no) 2017-06-12
US20120083488A1 (en) 2012-04-05
HUE028278T2 (en) 2016-12-28
PT2441753E (pt) 2016-06-16
EP3613729A1 (en) 2020-02-26
AU2010259588A1 (en) 2011-10-06
RU2585622C2 (ru) 2016-05-27
AR077025A1 (es) 2011-07-27
LT2975024T (lt) 2018-06-11
RU2015156881A3 (es) 2019-08-08
CR20110492A (es) 2012-03-08
NL300876I2 (nl) 2017-07-11
ES2668775T3 (es) 2018-05-22
HUE039167T2 (hu) 2018-12-28
RU2011154150A (ru) 2013-07-20

Similar Documents

Publication Publication Date Title
ECSP12011573A (es) Compuestos tetracíclicos
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
ECSP11010880A (es) Compuestos orgánicos
UY32730A (es) Inhibidores de cyp17
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
ECSP11011420A (es) Procedimientos para mejorar la farmacocinética
CR20120659A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
ECSP14013329A (es) Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CR20120448A (es) Compuesto heterocíclico
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
NI201300002A (es) Derivados de tetrahidro-pirido-pirimidina
CL2015002027A1 (es) Compuestos quimicos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
NI200900152A (es) Nuevo procedimiento de síntesis de la agomelatina
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2011001850A1 (es) Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.
BR112013028945A2 (pt) novos compostos de hexahidropirroloimidazolona